Retrospective Study on the Incidence and Management of Anemia in Oncology (RESPIRE)
The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).
Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.
Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Le Mans、法国、72000
- Centre Jean Bernard - Clinique Victor Hugo
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult patients with cancer and justifying continuous hospitalization for more than one night regardless of pattern.
Patient informed and not having expressed opposition to the study.
描述
Inclusion Criteria:
- Age ≥ 18 years old,
- Follow-up for cancer justifying hospitalization,
- Presenting anemia defined by a hemoglobin level <11 g / dL,
- Patient not having objected to the collection of his data after oral and written information.
Exclusion Criteria:
- patients with a hemoglobin level ≥ 11 g / dL,
- adult patients under guardianship, curatorship or deprived of liberty,
- pregnancy or breast-feeding in progress at the time of hospitalization.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
period 2011
|
evaluation of anemia status
|
|
period 2018
|
evaluation of anemia status
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of anemia
大体时间：2 years
|
number of patient with anemia (<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period
|
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of transfusion prescriptions
大体时间：2 years
|
number of transfusions performed on the number of patients hospitalized over the period
|
2 years
|
|
Assessment of erythropoiesis stimulating agents (EPO) prescriptions
大体时间：2 years
|
number of prescriptions for erythropoiesis stimulating agents (EPO)
|
2 years
|
|
Assessment of iron prescriptions
大体时间：2 years
|
number of prescriptions of iron (oral and intravenous)
|
2 years
|
|
Time between last transfusion and date of death
大体时间：2 years
|
Delay between the date of the last transfusion and the date of patient's death
|
2 years
|
|
overall survival
大体时间：2 years
|
Delay between the enrollment date and the date of patient's death
|
2 years
|
合作者和调查者
赞助
调查人员
- 首席研究员：Katell LE DÛ, MD、Centre Jean Bernard/Clinique Victor Hugo - LE MANS
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.